Lund Oct 4, 2011
NASDAQ OMX has approved EXINI Diagnostics AB (Publ) for listing at the market place of First North. First day of trading will be on Monday, October 10, 2011.
The trading of shares in EXINI will be moved to NASDAQ OMX First North on Monday, October 10. The last day of trading at AktieTorget will be on Friday, October 7. Shareholders do not need to take any action in the change.
Trading in the company's shares on NASDAQ OMX First North will be under the ticker EXINI and the current ISIN-code: SE0001810284. Certified Advisor for EXINI will be Thenberg & Kinde Fondkommission AB.
"The change of list to First North is expected to contribute to an increased international interest in EXINI as well as for the shares of the company, which is expected to aid the company's continued development and expansion", Magnus Aurell, CEO of EXINI Diagnostics AB, comments.
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46-286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI is working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Edenbrandt and currently has 13 employees. EXINI is listed on the stock market square and has about 400 shareholders. Principal owner, Bo Håkansson.
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com, VAT-no: SE556576199501